| RAPID AND SIGNIFICANT REDUCTION IN URIC ACID OBSERVED. ISELIN, N.J., April 5, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today provided an update on the ongoing clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and the principal investigator is John Sundy, MD, PhD an expert in the treatment of gout. The trial is d...continued PARS pharmaceutical biotechnology biotech |
Thursday, April 5, 2012
Pharmos Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment